Pasireotide LAR

DRUG13 trials

Sponsors

University of Pennsylvania, Novartis Pharmaceuticals, Mayo Clinic, RECORDATI GROUP, Columbia University

Conditions

ACTH-producing Pituitary TumourAcromegalyAutosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Liver DiseaseCushing's DiseaseDumping SyndromeEctopic ACTH Secreting (EAS) TumorsEctopic ACTH Syndrome

Phase 1

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

CompletedNCT01364415

Novartis PharmaceuticalsNeuroendocrine Tumors

Start: 2011-08-31End: 2016-04-30Updated: 2020-12-21

Phase 2

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

TerminatedNCT00929669

University of PennsylvaniaGonadotroph Adenomas

Start: 2009-06-30End: 2011-11-30Updated: 2017-11-28

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

TerminatedNCT00958841

Novartis PharmaceuticalsEctopic ACTH Syndrome, Nelson Syndrome, Pancreatic Neoplasm +1

Start: 2009-09-30End: 2015-06-30Updated: 2016-07-26

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

CompletedNCT01283542

Novartis PharmaceuticalsNon-functioning Pituitary Adenoma

Start: 2012-11-26End: 2017-09-12Updated: 2019-04-26

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

TerminatedNCT01374451

Novartis PharmaceuticalsIslet Cell Tumor

Start: 2011-06-30End: 2015-02-28Updated: 2016-12-20

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

CompletedNCT01563354

Novartis PharmaceuticalsNeuroendocrine Carcinoma of the Lung and Thymus

Start: 2013-08-16End: 2020-02-10Updated: 2021-04-02

Pasireotide LAR in Severe Polycystic Liver Disease

CompletedNCT01670110

Mayo ClinicAutosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease, Polycystic Liver Disease +1

Start: 2012-08-31End: 2018-09-30Updated: 2020-05-01

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

CompletedNCT01673646

Novartis PharmaceuticalsAcromegaly, Pituitary Gigantism

Start: 2012-10-16End: 2017-04-10Updated: 2019-09-16

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

TerminatedNCT02749227

Columbia UniversityACTH-producing Pituitary Tumour, Pituitary Tumor

Start: 2017-07-10End: 2020-03-31Updated: 2021-04-27

Phase 3

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

CompletedNCT01374906

Novartis PharmaceuticalsCushing's Disease

Start: 2011-11-04End: 2016-12-21Updated: 2018-05-22

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

CompletedNCT02354508

Novartis PharmaceuticalsAcromegaly

Start: 2015-03-31End: 2018-09-27Updated: 2019-12-10

Phase 4

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

CompletedNCT01794793

RECORDATI GROUPAcromegaly, Cushing's Disease, Dumping Syndrome +6

Start: 2013-06-10End: 2023-07-25Updated: 2024-10-01

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

CompletedNCT02060383

Novartis PharmaceuticalsAcromegaly, Cushing's Disease

Start: 2014-05-23End: 2018-03-26Updated: 2019-05-29

Related Papers

SUN-073 Long-Term Safety of Pasireotide in Patients With Cushing's Disease: Final Results From a 10-Year Open-Label Phase IV Rollover Study (B2412)

Journal of the Endocrine Society2025-10-01

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

Frontiers in Endocrinology2024-03-217 citations

Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study

Future Rare Diseases2024-03-19

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide

Journal of the Endocrine Society2023-10-012 citations

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial

Journal of the Endocrine Society2023-10-01

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

Pituitary2021-07-1852 citations

First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.

Journal of Clinical Oncology2021-05-206 citations

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement

Clinical Journal of the American Society of Nephrology2020-08-2537 citations

Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.

2020-05-0815 citations

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Frontiers in Endocrinology2020-02-0338 citations

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease

European Journal of Endocrinology2020-01-2759 citations

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.

2019-10-0114 citations

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

Clinical Endocrinology2019-08-2944 citations

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Frontiers in Endocrinology2019-07-1617 citations

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)

Journal of the Endocrine Society2019-04-011 citations

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

Journal of the Endocrine Society2019-04-011 citations

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

2017-10-23100 citations

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

2017-10-12117 citations

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

OncoTargets and Therapy2017-06-0118 citations

Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.

2016-10-0142 citations

2 more papers not shown